Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, according to the Swiss drugmaker.
Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
This new agreement builds on an earlier agreement for the fill and finish of more than 50 million doses at the Novartis Stein site in Switzerland in 2021.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…